Overview

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Status:
Active, not recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical cystectomy.

Phase:

Phase 2

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Gemcitabine
Pembrolizumab